Q32 Bio (QTTB) Cash & Current Investments (2017 - 2026)
Q32 Bio's quarterly Cash & Current Investments came in at $50.8 million in Q1 2026, down 22.5% year-on-year from $65.5 million in Q1 2025, and up 5.08% quarter-over-quarter from $48.3 million in Q4 2025.
Q32 Bio has reported Cash & Current Investments for 10 years, with the latest figure at $50.8 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments fell 22.5% year-over-year to $50.8 million; the trailing twelve-month figure through Mar 2026 stood at $50.8 million (down 22.5% YoY), and the FY2025 full-year result was $48.3 million, down 38.05% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $50.8 million, up from $48.3 million in the prior quarter.
- The five-year high for Cash & Current Investments was $256.1 million in Q1 2022, with the low at $25.6 million in Q4 2023.
- Average Cash & Current Investments over 5 years is $112.0 million, with a median of $89.1 million recorded in 2024.
- Year-over-year, Cash & Current Investments slumped 85.36% in 2023 and soared 204.35% in 2024.
- Tracing QTTB's Cash & Current Investments over 5 years: stood at $175.0 million in 2022, then tumbled by 85.36% to $25.6 million in 2023, then soared by 204.35% to $78.0 million in 2024, then sank by 38.05% to $48.3 million in 2025, then rose by 5.08% to $50.8 million in 2026.
- The last three Cash & Current Investments figures came in at $50.8 million (Q1 2026), $48.3 million (Q4 2025), and $68.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | 50.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.75 Mn |
| Dec 31, 2025 | 48.30 Mn |
| Sep 30, 2025 | 68.94 Mn |
| Jun 30, 2025 | 54.83 Mn |
| Mar 31, 2025 | 65.48 Mn |
| Dec 31, 2024 | 77.97 Mn |
| Sep 30, 2024 | 89.08 Mn |
| Jun 30, 2024 | 107.65 Mn |
| Mar 31, 2024 | 135.31 Mn |
| Dec 31, 2023 | 25.62 Mn |
| Sep 30, 2023 | 110.44 Mn |
| Jun 30, 2023 | 70.33 Mn |
| Mar 31, 2023 | 141.98 Mn |
| Dec 31, 2022 | 175.03 Mn |
| Sep 30, 2022 | 201.07 Mn |
| Jun 30, 2022 | 225.52 Mn |
| Mar 31, 2022 | 256.13 Mn |
| Dec 31, 2021 | 157.83 Mn |
| Sep 30, 2021 | 187.55 Mn |
| Jun 30, 2021 | 214.57 Mn |
| Mar 31, 2021 | 189.92 Mn |
| Dec 31, 2020 | 218.71 Mn |
| Sep 30, 2020 | 179.28 Mn |
| Jun 30, 2020 | 206.64 Mn |
| Mar 31, 2020 | 236.20 Mn |
| Dec 31, 2019 | 263.66 Mn |
| Sep 30, 2019 | 269.67 Mn |
| Jun 30, 2019 | 297.07 Mn |
| Mar 31, 2019 | 189.24 Mn |
| Dec 31, 2018 | 216.51 Mn |
| Sep 30, 2018 | 239.33 Mn |
| Jun 30, 2018 | 255.51 Mn |
| Mar 31, 2018 | 118.50 Mn |
| Dec 31, 2017 | 131.43 Mn |
| Sep 30, 2017 | 97.77 Mn |
| Jun 30, 2017 | 20.43 Mn |
| Mar 31, 2017 | 26.50 Mn |